NCT04594798

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (estimated)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Detailed description

In this study, the investigator would like to better understand the efficacy and safety of the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75 years and older.

Conditions

• DLBCL
• Lymphoma, B-Cell

Interventions

Type	Name	Description
DRUG	Polatuzumab vedotin	IV 1.8 mg/kg per cycle
DRUG	Rituximab	IV 375 mg/m2 per cycle
DRUG	Cyclophosphamide	IV 400 mg/m2 per cycle
DRUG	Doxorubicin	IV 25 mg/m2 per cycle
DRUG	Prednisone	PO 40 mg/m2 per cycle

Timeline

• Start date: 2021-09-20
• Primary completion: 2026-07-31
• Completion: 2026-07-31
• First posted: 2020-10-20
• Last updated: 2025-12-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study